| 產(chǎn)品名稱 | HL-60-Luc2 |
|---|---|
| 商品貨號(hào) | B161383 |
| Organism | Homo sapiens, human |
| Tissue | peripheral blood |
| Product Format | frozen 1.0 mL |
| Morphology | myoblastic |
| Culture Properties | suspension |
| Biosafety Level | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | acute promyelocytic leukemia |
| Age | 36 years |
| Gender | female |
| Ethnicity | Caucasian |
| Applications | Excellent signal/background ratio and stable luciferase expression make this cell line ideal for in vivo bioluminescence imaging of xenograft animal model to study human cancer and monitor activity of anti-cancer drug. It also can be used in cell-based assays for cancer research. |
| Storage Conditions | liquid nitrogen vapor phase |
| Tumorigenic | Yes, tested in Nu/Nu mice |
| Comments | This luciferase expressing cell line was derived from parental line CCL-240 by transduction with lentiviral vector encoding firefly luciferase gene (luc2) under control of EF-1 alpha promoter. This cell line was established through single cell cloning, and the cells constitutively express high levels of enzymatically active luciferase protein, which can be detected via in vitro and in vivo bioluminescence assays. The cells should be maintained in blasticidin (8 µg/mL) containing medium in routine cell culture. It is recommended to remove blasticidin prior to and during the experiment procedure when the cells are injected into animals in vivo, or co-cultured with other cell types in vitro. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium (IMDM, ATCC 30-2005). To make the complete growth medium, add the following components to the base medium:
|
| Subculturing | Cultures can be maintained by addition or replacement of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 105 cells/mL. Do not allow cell concentration to exceed 1 x 106 cells/mL. Maintain cell density between 1 X 105 and 1 X 106 cells/mL.
Medium Renewal: Every 2 to 3 days (depending on cell density). |
| Cryopreservation | IMDM supplemented with 9.5% FBS and 5% (v/v) DMSO (ATCC 4-X) |
| Culture Conditions | Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C |
| Cells per Vial | ≥ 1.0 x 106 cells |
| Volume | 1.0 mL |
| STR Profile | Amelogenin: X
CSF1PO: 13,14
D13S317: 8,11
D16S539: 11
D5S818: 12
D7S820: 11,12
THO1: 7,8
TPOX: 8,11
vWA: 16 |
| Sterility Tests | Bacteria and yeast: No growth Mycoplasma: No growth |
| Viral Testing | Hepatitis B: None detected Cytomegalovirus: None detected Human immunodeficiency virus: None detected Epstein-Barr virus: None detected Human papillomavirus: None detected |
| Functional Tests | Luciferase activity: signal to noise ≥ 1,000 RLUs In Vitro Luminesence: 20,000 photons/cell/sec, subject to imaging and culturing conditions |
| Population Doubling Time | approximately 19 hrs |
| Name of Depositor | ATCC |
| Year of Origin | 2018 |
| References | Zinn KR, et al. Noninvasive bioluminescence imaging in small animals. ILARJ 49: 103-115, 2008. PubMed: 18172337 Dothager RS, et al. Advances in bioluminescence imaging of live animal models. Curr Opin Biotechnol 20: 45-53, 2009. PubMed: 19233638 Gallagher R, et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 54: 713-733, 1979. PubMed: 288488 Collins SJ, et al. Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc. Natl. Acad. Sci. USA 75: 2458-2462, 1978. PubMed: 276884 Collins SJ, et al. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature 270: 347-349, 1977. PubMed: 271272 Aggarwal BB, et al. Human tumor necrosis factor. Production, purification, and characterization. J. Biol. Chem. 260: 2345-2354, 1985. PubMed: 3871770 Nahm MH, et al. Identification of cross-reactive antibodies with low opsonophogocytic activity for Streptoccus pneumoniae. J. Infect. Dis. 176: 698-703, 1997. PubMed: 9291318 Berninghausen O, Leippe M. Necrosis versus apoptosis as the mechanism of target cell death induced by Entamoeba histolytica. Infect. Immun. 65: 3615-3621, 1997. PubMed: 9284127 Aparicio CL, et al. Correction for label leakage in fluorimetric assays of cell adhesion. BioTechniques 23: 1056-1060, 1997. PubMed: 9421636 Mansat V, et al. The protein kinase C activators phorbol esters and phosphatidylserine inhibit neutral aphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin. Cancer Res. 57: 5300-5304, 1997. PubMed: 9393753 Cuthbert JA, Lipsky PE. Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism. Cancer Res. 57: 3498-3504, 1997. PubMed: 9270019 Michael JM, et al. Resistance to radiation-induced apoptosis in Burkitt's lumphoma cells is associated with defective ceramide signaling. Cancer Res. 57: 3600-3605, 1997. PubMed: 9270034 Clark RA, et al. Tenascin supports lymphocyte rolling. J. Cell Biol. 137: 755-765, 1997. PubMed: 9151679 Tiffany HL, et al. Enhanced expression of the eosinophil-derived neurotoin ribonuclease (RNS2) gene requires interaction between the promoter and intron. J. Biol. Chem. 271: 12387-12393, 1996. PubMed: 8647842 Chan YJ, et al. Synergistic interactions between overlapping binding sites for the serum response factor and ELK-1 proteins mediate both basal enhancement and phorbol ester responsiveness of primate cytomegalovirus. J. Virol. 70: 8590-8605, 1996. PubMed: 8970984 Mao M, et al. RIG-E, a human homolog of the murine Ly-6 family, is induced by retinoic acid during the differentiation of acute promyelocytic leukemia cell. Proc. Natl. Acad. Sci. USA 93: 5910-5914, 1996. PubMed: 8650192 Lepley RA, et al. Tyrosine kinase activity modulates catalysis and translocation of cellular 5-lipoxygenase. J. Biol. Chem. 271: 6179-6184, 1996. PubMed: 8626407 Chen H, et al. Octamer binding factors and their coactivator can activate the murine PU.1 (spi-1) promoter. J. Biol. Chem. 271: 15743-15752, 1996. PubMed: 8663022 U.S. Pharmacopeia USP Monographs: Technetium 99mTc Fanolesomab Injection. Rockville, MD: USP32-NF27, 2005 |
| 序號(hào) | 文章標(biāo)題 | 操作 |
|---|---|---|
| 1 | ATCC細(xì)胞運(yùn)輸和處理 | 查看詳情 |
| 2 | 其他海外品牌代理 | 查看詳情 |
| 3 | ATCC代理 | 查看詳情 |
| 4 | 購(gòu)買須知 | 查看詳情 |
| 5 | 訂購(gòu)流程 | 查看詳情 |
| 梅經(jīng)理 | 17280875617 | 1438578920 |
| 胡經(jīng)理 | 13345964880 | 2438244627 |
| 周經(jīng)理 | 17757487661 | 1296385441 |
| 于經(jīng)理 | 18067160830 | 2088210172 |
| 沈經(jīng)理 | 19548299266 | 2662369050 |
| 李經(jīng)理 | 13626845108 | 972239479 |
